Shares of Regulus Therapeutics fell back near their already-reduced initial public offering level this week, suggesting that Wall Street may be less willing to embrace microRNA therapeutics than may have been anticipated.

By mid-morning Thursday, shares of Regulus were selling around $4.15, just $0.15 over the price at which they debuted to the public on Oct. 5.

To Byron Capital Markets analyst Doug Loe, the tepid response to Regulus' IPO is likely due to a combination of factors, most notably the early-stage nature of its product candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.